Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| QuidelOrtho CorpQDEL · Entity 4986 | Chief Legal Officer | April 15, 2026 | April 22, 2026 |
| STAAR SURGICAL COSTAA · Entity 4851 | Chief Legal Officer | December 11, 2025 | December 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
QuidelOrtho Corp
Report date April 15, 2026 · Filed April 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 73,435 |
Reported balance
After 2026-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-15 · Grant · Acquired 73,435 · Balance 73,435 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: 24,478 shares will vest in equal installments on April 15, 2027 and April 15, 2028; the remaining 24,479 shares will vest on April 15, 2029. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $17.49 · Expires 2036-04-15 | Direct | 73,434 |
Reported balance
After 2026-04-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-15 · Grant · Acquired 73,434 · Balance 73,434 F3: 24,478 shares will vest in equal installments on April 15, 2027, April 15, 2028 and April 15, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F2: 24,478 shares will vest in equal installments on April 15, 2027 and April 15, 2028; the remaining 24,479 shares will vest on April 15, 2029.
F3: 24,478 shares will vest in equal installments on April 15, 2027, April 15, 2028 and April 15, 2029.
STAAR SURGICAL CO
Report date December 11, 2025 · Filed December 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,812 |
Reported balance
After 2025-12-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-11 · Tax withholding · Disposed 2,616 · Balance 22,812 F1: On December 11, 2025, restricted stock units (RSUs) granted to the reporting person on December 11, 2023, and reported on a Form 4 filed on December 12, 2023, vested as to 7,312 shares. Upon vesting, 2,616 shares were withheld to satisfy taxes. F2: Includes previously granted RSUs, which are subject to future vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 11, 2025, restricted stock units (RSUs) granted to the reporting person on December 11, 2023, and reported on a Form 4 filed on December 12, 2023, vested as to 7,312 shares. Upon vesting, 2,616 shares were withheld to satisfy taxes.
F2: Includes previously granted RSUs, which are subject to future vesting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NUVASIVE INC
Report date September 01, 2023 · Filed September 05, 2023
Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 1
1 source rowRow 1 · 2023-09-01 · Disposition to issuer · Disposed 22,423 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-01 · Disposition to issuer · Disposed 5,893 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-01 · Disposition to issuer · Disposed 6,421 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-01 · Disposition to issuer · Disposed 16,405 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. |
| Performance Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-01 · Disposition to issuer · Disposed 5,893 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F4: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time. |
| Performance Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-01 · Disposition to issuer · Disposed 6,421 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F4: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.
F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.
F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time.
F4: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2026 Filed Apr 22, 2026 18:14 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 73,434 | $0.00 Strike: $17.49 | $0.00 |
DisclosureSEC source: 0001225738-26-000007 · wk-form4_1776896045.xml · derivative · entry 2 SISITSKY NATHANIEL · CIK 0001225738 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,434 Underlying: Common Stock · 73,434 shares Expires 2036-04-15 F3 · derivative.exercise_date: 24,478 shares will vest in equal installments on April 15, 2027, April 15, 2028 and April 15, 2029. Read SEC document |
| April 15, 2026 Filed Apr 22, 2026 18:14 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 73,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001225738-26-000007 · wk-form4_1776896045.xml · derivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,435 Underlying: Common Stock · 73,435 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 24,478 shares will vest in equal installments on April 15, 2027 and April 15, 2028; the remaining 24,479 shares will vest on April 15, 2029. F2 · derivative.expiration_date: 24,478 shares will vest in equal installments on April 15, 2027 and April 15, 2028; the remaining 24,479 shares will vest on April 15, 2029. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 01:07 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Tax withholdingCommon Stock | 2,616 | $24.68 | $64,562.88 |
DisclosureSEC source: 0001193125-25-318018 · ownership.xml · nonDerivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,812 F1 · security: On December 11, 2025, restricted stock units (RSUs) granted to the reporting person on December 11, 2023, and reported on a Form 4 filed on December 12, 2023, vested as to 7,312 shares. Upon vesting, 2,616 shares were withheld to satisfy taxes. F2 · balance_after: Includes previously granted RSUs, which are subject to future vesting. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:03 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantRestricted Stock Units · Derivative | 8,798 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-041513 · ownership.xml · derivative · entry 2 SISITSKY NATHANIEL · CIK 0001225738 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,798 Underlying: Common Stock · 8,798 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive one share of the Corporation's common stock upon vesting. F3 · derivative.exercise_date: Reflects RSUs granted to the Reporting Person on March 14, 2025 in connection with the Reporting Person's promotion to Chief Legal Officer. These RSUs vest as to 1/3 (2,932 shares) on March 14, 2026, 1/3 (2,933 shares) on March 14, 2027, and 1/3 (2,933 shares) on March 14, 2028. F3 · derivative.expiration_date: Reflects RSUs granted to the Reporting Person on March 14, 2025 in connection with the Reporting Person's promotion to Chief Legal Officer. These RSUs vest as to 1/3 (2,932 shares) on March 14, 2026, 1/3 (2,933 shares) on March 14, 2027, and 1/3 (2,933 shares) on March 14, 2028. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:03 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantRestricted Stock Units · Derivative | 43,989 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-041513 · ownership.xml · derivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,989 Underlying: Common Stock · 43,989 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive one share of the Corporation's common stock upon vesting. F2 · derivative.exercise_date: Reflects RSUs granted to the Reporting Person on March 14, 2025 in connection with annual equity award. These RSUs vest as to 1/3 (14,663 shares) on March 14, 2026, 1/3 (14,663 shares) on March 14, 2027, and 1/3 (14,663 shares) on March 14, 2028. F2 · derivative.expiration_date: Reflects RSUs granted to the Reporting Person on March 14, 2025 in connection with annual equity award. These RSUs vest as to 1/3 (14,663 shares) on March 14, 2026, 1/3 (14,663 shares) on March 14, 2027, and 1/3 (14,663 shares) on March 14, 2028. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 23:20 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionRestricted Stock Units · Derivative | 5,827 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-039703 · ownership.xml · derivative · entry 3 SISITSKY NATHANIEL · CIK 0001225738 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,654 Underlying: Common Stock · 5,827 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the right to receive one share of the Corporation's common stock upon vesting. F1 · derivative.exercise_date: Reflects restricted stock units (RSUs) granted to the Reporting Person on March 12, 2024. These RSUs vested as to 1/3 (5,827 shares) on March 12, 2025, and will vest as 1/3 (5,827 shares) on March 12, 2026, and 1/3 (5,827 shares) on March 12, 2027. F1 · derivative.expiration_date: Reflects restricted stock units (RSUs) granted to the Reporting Person on March 12, 2024. These RSUs vested as to 1/3 (5,827 shares) on March 12, 2025, and will vest as 1/3 (5,827 shares) on March 12, 2026, and 1/3 (5,827 shares) on March 12, 2027. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 23:20 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Tax withholdingCommon Stock | 2,334 | $18.00 | $42,012.00 |
DisclosureSEC source: 0000950170-25-039703 · ownership.xml · nonDerivative · entry 2 SISITSKY NATHANIEL · CIK 0001225738 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,428 F2 · shares: Shares withheld by the Corporation to satisfy tax withholding obligations. F3 · balance_after: Includes previously granted RSUs, which are subject to future vesting. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 23:20 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 5,827 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-039703 · ownership.xml · nonDerivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects restricted stock units (RSUs) granted to the Reporting Person on March 12, 2024. These RSUs vested as to 1/3 (5,827 shares) on March 12, 2025, and will vest as 1/3 (5,827 shares) on March 12, 2026, and 1/3 (5,827 shares) on March 12, 2027. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:17 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock Options · Derivative | 15,657 | $0.00 Strike: $37.64 | $0.00 |
DisclosureSEC source: 0000950170-24-031667 · ownership.xml · derivative · entry 2 SISITSKY NATHANIEL · CIK 0001225738 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,657 Underlying: Common Stock · 15,657 shares Expires 2034-03-11 F3 · derivative.exercise_date: Stock options granted to the Reporting Person on March 12, 2024. Options will vest and become exercisable as to 1/3 (5,219 shares) on March 12, 2025, with the remaining 2/3 (10,438 shares) vesting and becoming exercisable monthly over the following 24 months in equal amounts on a monthly basis. In the event such amount does not evenly divide into 24 months, the remaining balance of options will vest and become exercisable on March 12, 2027. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:17 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantRestricted Stock Units · Derivative | 17,481 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-031667 · ownership.xml · derivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,481 Underlying: Common Stock · 17,481 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive one share of the Corporation's common stock upon vesting. F2 · derivative.exercise_date: RSUs granted to the Reporting Person on March 12, 2024. RSUs will vest as to 1/3 (5,827 shares) on March 12, 2025, 1/3 (5,827 shares) on March 12, 2026, and 1/3 (5,827 shares) on March 12, 2027. F2 · derivative.expiration_date: RSUs granted to the Reporting Person on March 12, 2024. RSUs will vest as to 1/3 (5,827 shares) on March 12, 2025, 1/3 (5,827 shares) on March 12, 2026, and 1/3 (5,827 shares) on March 12, 2027. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 23:31 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock Options · Derivative | 39,860 | $0.00 Strike: $32.14 | $0.00 |
DisclosureSEC source: 0001209191-23-058370 · doc4.xml · derivative · entry 2 SISITSKY NATHANIEL · CIK 0001225738 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,860 Underlying: Common Stock · 39,860 shares Expires 2033-12-10 F2 · derivative.exercise_date: The options granted become exercisable as follows: 1/3 on 12/11/2024 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 12/11/2026. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 23:31 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock | 21,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058370 · doc4.xml · nonDerivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,935 F1 · shares: Award of 21935 Restricted Stock Units of Common Stock (RSU), subject to forfeiture rights, which lapse as to 1/3 of the RSUs on 12/11/2024, 1/3 of the RSUs on 12/11/2025, and the remaining 1/3 of the RSUs on 12/11/2026. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:34 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerPerformance Restricted Stock Unit · Derivative | 6,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048173 · doc4.xml · derivative · entry 6 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,421 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:34 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerPerformance Restricted Stock Unit · Derivative | 5,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048173 · doc4.xml · derivative · entry 5 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,893 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each performance restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio and with applicable performance conditions deemed to be achieved at 100% of the target performance level. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions but excluding performance-based vesting conditions) as applied to the corresponding Issuer performance restricted stock unit award subject to such award as of immediately prior to the Effective Time. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:34 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerRestricted Stock Unit · Derivative | 16,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048173 · doc4.xml · derivative · entry 4 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,405 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:34 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerRestricted Stock Unit · Derivative | 6,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048173 · doc4.xml · derivative · entry 3 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,421 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:34 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerRestricted Stock Unit · Derivative | 5,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048173 · doc4.xml · derivative · entry 2 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,893 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award was converted into a Globus restricted stock unit award, with the number of shares of Globus Class A Common Stock subject to such assumed award determined based on the Exchange Ratio. Each converted Globus restricted stock unit award is subject to the same terms and conditions (including service-based vesting conditions) as applied to the corresponding Issuer restricted stock unit award as of immediately prior to the Effective Time. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:34 UTC | NUVASIVE INC NUVA · Entity 110002 | Disposition to issuerCommon Stock, par value $0.001 per share | 22,423 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-048173 · doc4.xml · nonDerivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 16,405 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015851 · doc4.xml · derivative · entry 4 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,405 Underlying: Common Stock · 16,405 shares Expires not disclosed F3 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F5 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 1, 2023. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2026. F5 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 1, 2023. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2026. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 5,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015851 · doc4.xml · derivative · entry 3 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 2, 2020. In accordance with the terms of the RSU award, the award vested as to 5,333 shares on March 1, 2023. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 2, 2020. In accordance with the terms of the RSU award, the award vested as to 5,333 shares on March 1, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 1,976 | $42.67 | $84,315.92 |
DisclosureSEC source: 0001209191-23-015851 · doc4.xml · nonDerivative · entry 2 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,864 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Amount includes 457 shares acquired under the Issuer's employee stock purchase plan in April 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 5,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015851 · doc4.xml · nonDerivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Amount includes 457 shares acquired under the Issuer's employee stock purchase plan in April 2022. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 17:51 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 6,421 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015766 · doc4.xml · derivative · entry 5 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,421 Underlying: Common Stock · 6,421 shares Expires not disclosed F5 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F7 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 1, 2022. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2025. F7 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 1, 2022. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2025. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 17:51 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 5,130 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015766 · doc4.xml · derivative · entry 4 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,130 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F6 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 1, 2019. In accordance with the terms of the RSU award, the award vested as to 5,130 shares on March 1, 2022. F6 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 1, 2019. In accordance with the terms of the RSU award, the award vested as to 5,130 shares on March 1, 2022. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 17:51 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionPRSUs · Derivative | 2,899 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015766 · doc4.xml · derivative · entry 3 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,899 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2019. In accordance with the terms of the PRSU award, the award vested as to 2,899 shares on March 1, 2022. F4 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2019. In accordance with the terms of the PRSU award, the award vested as to 2,899 shares on March 1, 2022. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 17:51 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 2,868 | $54.51 | $156,334.68 |
DisclosureSEC source: 0001209191-22-015766 · doc4.xml · nonDerivative · entry 2 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,050 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 17:51 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 8,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015766 · doc4.xml · nonDerivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 17:52 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 2,899 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009440 · doc4.xml · derivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,899 Underlying: Common Stock · 2,899 shares Expires not disclosed F1 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2019. The award was granted based on a target number of shares with a performance multiplier of 0-200% based on the Issuer's non-GAAP Operating Margin over the performance period ended December 31, 2021. On February 10, 2022, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 2,899 shares on March 1, 2022, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2019. The award was granted based on a target number of shares with a performance multiplier of 0-200% based on the Issuer's non-GAAP Operating Margin over the performance period ended December 31, 2021. On February 10, 2022, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 2,899 shares on March 1, 2022, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Read SEC document |
| April 30, 2021 Filed May 4, 2021 17:56 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 2,256 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030010 · doc4.xml · derivative · entry 4 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,256 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F6 · derivative.exercise_date: This RSU award was granted to the Reporting Person on April 30, 2018. In accordance with the terms of the RSU award, the award vested as to 2,256 shares on April 30, 2021. F6 · derivative.expiration_date: This RSU award was granted to the Reporting Person on April 30, 2018. In accordance with the terms of the RSU award, the award vested as to 2,256 shares on April 30, 2021. Read SEC document |
| April 30, 2021 Filed May 4, 2021 17:56 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionPRSUs · Derivative | 237 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030010 · doc4.xml · derivative · entry 3 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on April 30, 2018. In accordance with the terms of the PRSU award, the award vested as to 237 shares on April 30, 2021. F4 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on April 30, 2018. In accordance with the terms of the PRSU award, the award vested as to 237 shares on April 30, 2021. Read SEC document |
| April 30, 2021 Filed May 4, 2021 17:56 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 861 | $71.45 | $61,518.45 |
DisclosureSEC source: 0001209191-21-030010 · doc4.xml · nonDerivative · entry 2 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,889 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Amount includes 354 shares acquired under the Issuer's employee stock purchase plan in April 2020 and 555 shares acquired under the Issuer's employee stock purchase plan in April 2021. Read SEC document |
| April 30, 2021 Filed May 4, 2021 17:56 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 2,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030010 · doc4.xml · nonDerivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Amount includes 354 shares acquired under the Issuer's employee stock purchase plan in April 2020 and 555 shares acquired under the Issuer's employee stock purchase plan in April 2021. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:57 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 5,893 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017159 · doc4.xml · derivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,893 Underlying: Common Stock · 5,893 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 1, 2021. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2021. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 1, 2021. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2021. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 17:50 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 237 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010343 · doc4.xml · derivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237 Underlying: Common Stock · 237 shares Expires not disclosed F1 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on April 30, 2018. The award was granted based on a target number of shares with a performance multiplier of 0-200% based on the Issuer's non-GAAP Operating Margin over the performance period ended December 31, 2020. On February 10, 2021, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 237 shares on April 30, 2021, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on April 30, 2018. The award was granted based on a target number of shares with a performance multiplier of 0-200% based on the Issuer's non-GAAP Operating Margin over the performance period ended December 31, 2020. On February 10, 2021, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 237 shares on April 30, 2021, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 17:51 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 5,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015523 · doc4.xml · derivative · entry 4 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,333 Underlying: Common Stock · 5,333 shares Expires not disclosed F3 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F5 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 2, 2020. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2023. F5 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 2, 2020. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2023. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 17:51 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 1,586 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015523 · doc4.xml · derivative · entry 3 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,586 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 1, 2017. In accordance with the terms of the RSU award, the award vested as to 1,586 shares on March 1, 2020. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 1, 2017. In accordance with the terms of the RSU award, the award vested as to 1,586 shares on March 1, 2020. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 17:51 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 604 | $65.81 | $39,749.24 |
DisclosureSEC source: 0001209191-20-015523 · doc4.xml · nonDerivative · entry 2 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,348 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 17:51 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 1,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015523 · doc4.xml · nonDerivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:52 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 1,710 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-041253 · doc4.xml · derivative · entry 3 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This RSU award was granted to the Reporting Person on July 1, 2015. In accordance with the terms of the RSU award, the award vested as to 1,710 shares on each of July 1, 2016, July 1, 2017, July 1, 2018 and July 1, 2019. F3 · derivative.expiration_date: This RSU award was granted to the Reporting Person on July 1, 2015. In accordance with the terms of the RSU award, the award vested as to 1,710 shares on each of July 1, 2016, July 1, 2017, July 1, 2018 and July 1, 2019. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:52 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 591 | $56.95 | $33,657.45 |
DisclosureSEC source: 0001209191-19-041253 · doc4.xml · nonDerivative · entry 2 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,366 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Amount includes 436 shares acquired under the Issuer's employee stock purchase plan in April 2019. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:52 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-041253 · doc4.xml · nonDerivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Amount includes 436 shares acquired under the Issuer's employee stock purchase plan in April 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:57 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 5,130 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016863 · doc4.xml · derivative · entry 5 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,130 Underlying: Common Stock · 5,130 shares Expires not disclosed F5 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F7 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 1, 2019. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2022. F7 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 1, 2019. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:57 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 3,721 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016863 · doc4.xml · derivative · entry 4 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,721 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F6 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 1, 2016. In accordance with the terms of the RSU award, the award vested as to 3,721 shares on March 1, 2019. F6 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 1, 2016. In accordance with the terms of the RSU award, the award vested as to 3,721 shares on March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:57 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionPRSUs · Derivative | 1,229 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016863 · doc4.xml · derivative · entry 3 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,229 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2016. In accordance with the terms of the PRSU award, the award vested as to 1,229 shares on March 1, 2019. F4 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2016. In accordance with the terms of the PRSU award, the award vested as to 1,229 shares on March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:57 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 1,768 | $58.48 | $103,392.64 |
DisclosureSEC source: 0001209191-19-016863 · doc4.xml · nonDerivative · entry 2 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,811 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:57 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 4,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016863 · doc4.xml · nonDerivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| February 06, 2019 Filed Feb 7, 2019 18:00 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 1,229 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008198 · doc4.xml · derivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,229 Underlying: Common Stock · 1,229 shares Expires not disclosed F1 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2016. The award was granted based on a target number of shares with a performance multiplier of 0-250% based on the Issuer's total stockholder return over the performance period ended December 31, 2018. On February 6, 2019, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 1,229 shares on March 1, 2019, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2016. The award was granted based on a target number of shares with a performance multiplier of 0-250% based on the Issuer's total stockholder return over the performance period ended December 31, 2018. On February 6, 2019, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 1,229 shares on March 1, 2019, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 17:58 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 1,710 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-041281 · doc4.xml · derivative · entry 3 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,710 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This RSU award was granted to the Reporting Person on July 1, 2015. In accordance with the terms of the RSU award, the award vested as to 1,710 shares on each of July 1, 2016, July 1, 2017 and July 1, 2018 and will vest as to 1,710 shares on July 1, 2019. F3 · derivative.expiration_date: This RSU award was granted to the Reporting Person on July 1, 2015. In accordance with the terms of the RSU award, the award vested as to 1,710 shares on each of July 1, 2016, July 1, 2017 and July 1, 2018 and will vest as to 1,710 shares on July 1, 2019. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 17:58 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 589 | $52.12 | $30,698.68 |
DisclosureSEC source: 0001209191-18-041281 · doc4.xml · nonDerivative · entry 2 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,629 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 17:58 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-041281 · doc4.xml · nonDerivative · entry 1 SISITSKY NATHANIEL · CIK 0001225738 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.